Independent Financial Group LLC Invests $642,000 in Novartis AG $NVS

Independent Financial Group LLC bought a new position in shares of Novartis AG (NYSE:NVS) in the first quarter, Holdings Channel reports. The institutional investor bought 4,205 shares of the company’s stock, valued at approximately $642,000.

Several other institutional investors have also recently added to or reduced their stakes in NVS. BXM Wealth LLC grew its position in Novartis by 726.9% during the 4th quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock worth $5,903,000 after acquiring an additional 37,639 shares during the last quarter. Spire Wealth Management raised its position in Novartis by 2,561.0% in the 4th quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock valued at $5,375,000 after purchasing an additional 37,518 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Novartis by 14.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company’s stock worth $15,681,000 after purchasing an additional 14,352 shares in the last quarter. HF Advisory Group LLC grew its holdings in shares of Novartis by 401.0% during the fourth quarter. HF Advisory Group LLC now owns 54,741 shares of the company’s stock worth $7,547,000 after purchasing an additional 43,814 shares during the last quarter. Finally, Concurrent Investment Advisors LLC increased its stake in shares of Novartis by 36.6% in the fourth quarter. Concurrent Investment Advisors LLC now owns 14,815 shares of the company’s stock valued at $2,043,000 after buying an additional 3,967 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

NVS has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Finally, Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $141.20.

Novartis Stock Down 0.5%

NYSE:NVS opened at $153.04 on Thursday. The company has a market cap of $292.02 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 2.66 and a beta of 0.45. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The stock’s fifty day moving average price is $151.68 and its two-hundred day moving average price is $151.99. Novartis AG has a 52-week low of $112.34 and a 52-week high of $170.46.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.23% and a net margin of 23.29%. On average, analysts anticipate that Novartis AG will post 8.75 EPS for the current year.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis beat Q2 estimates, reporting EPS of $2.41 versus $2.20 expected and revenue of $14.41 billion versus $14.07 billion expected, driven by strong sales in key brands and lower costs. Article Title
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests the company is still confident that growth from newer drugs can outweigh declines in older products. Article Title
• Positive Sentiment: Several articles also pointed to a more constructive investor view, including a Seeking Alpha “buy thesis” upgrade and commentary that Novartis returned to sales growth as newer medicines offset generic pressure. Article Title
• Neutral Sentiment: CEO Vas Narasimhan said there is “no change of plans,” with key clinical trial readouts expected in the second half of the year. That keeps the pipeline story in focus, but it is still a waiting game. Article Title
• Negative Sentiment: Investors are still watching for headwinds from generic competition and steep sales declines in Entresto, which could limit how quickly Novartis can sustain growth. Article Title

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.